@article {118,
	title = {Saroglitazar: India{\textquoteright}s Answer to Diabetic Dyslipidemia},
	journal = {International Journal of Pharmacology and Clinical Sciences},
	volume = {3},
	year = {2014},
	month = {March 2014},
	pages = {7-14},
	type = {New drug information},
	chapter = {7},
	abstract = {<p class="rtejustify">Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the globe. A novel target to control this disorder has agonistic activity on peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ receptors simultaneously. While the α form has lipid lowering effects, γ leads to lowering in blood glucose. Saroglitazar (Lipaglyn), developed by Zydus Cadila, first new chemical entity (NCE) discovered and developed indige-nously by an Indian Pharma Company, has agonistic activity on both PPAR-α and PPAR-γ receptors. Unlike other glitazars that were discontinued during their development, saroglitazar enjoys a high benefit-to-risk ratio. It is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by conventional therapy. Dose recommended for Lipaglyn is 4mg once a day.</p>
},
	keywords = {Diabetic dyslipidemia, Glitazar, PPAR-α, PPAR-γ agonist, Saroglitazar},
	author = {Akanksha Aggarwal}
}
